Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Anti-CD19 CAR-T Therapy in r/r B-ALL
NCT07695012Phase 1Recruiting
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous anti-CD19 CAR-T cells in acute lymphoblastic leukemia (ALL). Primary endpoint: Safety and feasibility of autologous anti-CD19 CAR-T cell therapy at 1 year. Started Jun 2026; status: recruiting.
02
Drugs
autologous anti-CD19 CAR-T cells
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07695012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07695012.